LDS/Medical Tests/Cardiac Myosin Binding Protein C (MYBPC3) Mutation Analysis

Cardiac Myosin Binding Protein C (MYBPC3) Mutation Analysis

The MYBPC3 gene, located in the short (p) arm of chromosome 11 at position 11.2 encodes cardiac myosin binding protein c (cMyBP-C). Cardiac myosin binding protein c is a 140.5 kDa protein composed of 1273 amino acids expressed exclusively in cardiac muscle sarcomeres where it attaches to thick filaments through phosphate groups. Cardiac MyBP-C is the only myofilament protein that can link the thick and thin filaments within the region of active cross-bridge cycling. When the phosphate groups are removed, cMyBP-C is broken down, followed by the breakdown of proteins in the thick filament.

Most of the known MYBPC3 mutations (>60%) are truncating mutations, including nonsense mutations, insertions or deletions, splicing or branch point mutations. Mutations in MYBPC3 are a common cause of familial hypertrophic cardiomyopathy (FHCM) and account for 45-50% of cases. It is typically inherited in an autosomal dominant manner although rare recessive and de novo mutations have been identified. FHCM is characterized by unexplained left ventricular (LV) hypertrophy (thickening) associated with non-dilated ventricular chambers. The primary defect in FHCM caused by MYBCP3 mutations is an alteration in the normal contraction / relaxation cycle of cardiac muscle giving rise to stimuli that promote cellular hypertrophy and ventricular remodeling.

Pathological features of FHCM include myocardial fiber hypertrophy, disorganized myocardial cells, interstitial fibrosis and thickened intra-myocardial coronary vessels. Clinically the disorder is quite variable and only 25% of FHCM patients develop symptom such as dyspnea, syncope, collapse, palpitations, and chest pain. There is also inter- and intra-familial variability ranging from clinically benign to malignant forms that have a high risk of cardiac failure and sudden cardiac death. FHCM is the most common cause of sudden cardiac death in young people with the prevalence of 1:500 in the general adult population.

MYBPC3 mutations can lead to other forms of cardiomyopathies, such as dilated cardiomyopathy (DCM) and left ventricular non-compaction (LVNC), the latter being characterized by prominent trabeculation of the left ventricle and deep intertrabecular recesses. In addition, bi-allelic truncating MYBPC3 mutations are associated with neonatal cardiomyopathy and lead to heart failure and death within the first year of life. Dilated cardiomyopathy (DCM) is most commonly inherited in an autosomal dominant or X-linked manner. DCM is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. DCM is the most common cause of congestive heart failure in young patients, though, conduction impairment, syncope and sudden death may also occur. Its prevalence is about 1 in 2,500 in adult populations. Many people with dilated cardiomyopathy have no or only mild symptoms and live a normal life. Other DCM patients may develop symptoms such as fatigue, weight loss, fainting, palpitations, chest pain and sudden death. Mutations in MYBPC3 account for 2-4% of patients with DCM.s

  • As an aid in diagnosis of familial hypertrophic cardiomyopathy and dilated cardiomyopathy
  • Carrier screening for relatives and those with the family history
  • Prenatal carrier screening for those with the family history
Mutation or pathogenic variants in MYBPC3 gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

Target sequencing by next generation sequencing (NGS), deletion/duplication analysis by quantitative multiplex PCR, long-range PCR, multiplex ligation dependent probe amplification (MLPA).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
Creatine kinase (CK), CK-MB, lactate dehydrogenase (LDH), troponin T, myosin light chain-1 (MLC-1), electrocardiogram, chest X-ray, exercise stress echocardiography, cardiac catheterization and magnetic resonance imaging (MRI).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Gene. 2015; 573: 188–197. [PMID: 26358504]
  • J Card Fail. 2012; 18: 296-303. [PMID: 22464770]
  • Circ Res. 2004;94: 1279-89. [PMID: 15166115]
  • Compr Physiol. 2018; 8: 631-709. [PMID: 29687901]
  • Proc Natl Acad Sci U S A. 2017; 114: E1355-E1364. [PMID: 28167762]
  • BMC Med Genet. 2014;15: 99. [PMID: 25224718]
  • Emery and Rimoin’s Principles and Practice of Medical Genetics, in: Chapter 47, inherited cardiomyopathies, 2013: 1-38. doi:10.1016/b978-0-12-383834-6.00053-7